Literature DB >> 29436450

Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine.

Thomas Burden1, Charlotte Thompson1, Efstathios Bonanos1, Andrew Rl Medford2.   

Abstract

A 71-year-old female with a history of pulmonary embolism treated with rivaroxaban presented with acute onset shortness of breath, chest pain and palpitations. Computed tomographic pulmonary angiography (CTPA) revealed multiple bilateral pulmonary emboli. The patient was concurrently prescribed carbamazepine and was later diagnosed with recurrence of breast cancer during the admission. We discuss common drug interactions pertinent to direct oral anticoagulants (DOACs) that can increase the risk of further venous thromboembolism. This case report highlights the importance of reviewing patient medications when considering anticoagulants and the need to raise awareness of these drug interactions among clinicians when making their choice of anticoagulation. It also reinforces the current lack of evidence for use of DOACs in patients with solid organ malignancies. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  CYP3A4; Pulmonary embolism; carbamazepine; direct oral anticoagulants; drug interactions; rivaroxaban

Mesh:

Substances:

Year:  2018        PMID: 29436450      PMCID: PMC6330908          DOI: 10.7861/clinmedicine.18-1-103

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  5 in total

1.  [Pulmonary embolism due to interaction between rivaroxaban and carbamazepine].

Authors:  Arne J Risselada; Martin J Visser; Eric N van Roon
Journal:  Ned Tijdschr Geneeskd       Date:  2013

Review 2.  Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

Authors:  Nick van Es; Michiel Coppens; Sam Schulman; Saskia Middeldorp; Harry R Büller
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

3.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

4.  Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.

Authors:  Wolfgang Mueck; Dagmar Kubitza; Michael Becka
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

5.  Treatment options for venous thromboembolism: lessons learnt from clinical trials.

Authors:  Simon McRae
Journal:  Thromb J       Date:  2014-12-08
  5 in total
  5 in total

Review 1.  Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.

Authors:  Sara R Vazquez
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs).

Authors:  Indrajit Chattopadhyay; Vedamurthy Adhiyaman; Suhani Ghiya
Journal:  Clin Med (Lond)       Date:  2018-06       Impact factor: 2.659

3.  Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).

Authors:  Amichai Perlman; Maor Wanounou; Rachel Goldstein; Lotan Choshen Cohen; Daniel E Singer; Mordechai Muszkat
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 4.  Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT).

Authors:  Nikolaos Tsoukalas; Norman Brito-Dellan; Carme Font; Taylor Butler; Cristhiam M Rojas-Hernandez; Thomas Butler; Carmen Escalante
Journal:  Support Care Cancer       Date:  2022-08-06       Impact factor: 3.359

5.  Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study.

Authors:  Amichai Perlman; Rachel Goldstein; Lotan Choshen Cohen; Bruria Hirsh-Raccah; David Hakimian; Ilan Matok; Yosef Kalish; Daniel E Singer; Mordechai Muszkat
Journal:  CNS Drugs       Date:  2021-02-17       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.